Reading BNTC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BNTC free→Reading BNTC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BNTC free→QuarterlyIQ Insights · BNTC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Director On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date. Mr. Friedman was appointed as a Class III member of the Board with a term lasting until the Company’s 2028 annual meeting of stockholders. In co…
Results of Operations and Financial Condition. On May 14, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2026 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Results of Operations and Financial Condition. On February 12, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended December 31, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Results of Operations and Financial Condition. On November 14, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Entry into a Material Definitive Agreement. Underwritten Offering On November 5, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”), TD Securities (USA) LLC (“TD Securities”) and Evercore Group L.L.C. (“Evercore ISI”), as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell, in…
Other Events. On November 5, 2025, the Company issued a press release announcing that it had priced the Offerings. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Forward-Looking Statements This Current Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company has tried to identif…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 2, 2025, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed Dr. Sharon Mates to serve as a director of the Board, effective as of November 3, 2025. Dr. Mates was appointed as a Class I member of the Board with a term lasting until the Company’s 2026 annual meeting of stockholders. The Board has dete…
Results of Operations and Financial Condition. On September 22, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year ended June 30, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. In connection with the preparation of Benitec Biopharma Inc.’s (“Benitec,” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K”), the Company determined that in prior periods it had not appropriately recorded certain non-cash share-based compensation expenses . Accordingly, on September 10, 2025, the Audit Committee (the “Audit Com…
Results of Operations and Financial Condition. On May 14, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Entry into a Material Definitive Agreement. On March 26, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”) entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. (together, the “Purchasers”) in connection with the closing of the previously announced registered direct offering conducted by the Company pursuant to the Registration Statement on Form S-3 (File No. 333- 282957), as s…
Other Events. On March 25, 2025, the Company issued a press release announcing that it had priced the Offerings, and that in connection with the Direct Offering it has discussed with Suvretta Capital appointing David Friedman, managing director at Suvretta Capital, to the Company’s board of directors, subject to approval by the Company’s board of directors and review by its Nominating and Governance Committee. A copy of the press release is attached as Exhibit 99.1 to this Current Report and…
Entry into a Material Definitive Agreement. Underwritten Offering On March 25, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”) and TD Securities (USA) LLC (“TD Cowen”), as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell, in an underwritten offering by the Company (the “U…
Results of Operations and Financial Condition. On February 14, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2024 and an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.